164 related articles for article (PubMed ID: 21385558)
1. Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis.
Sumida K; Ubara Y; Takemoto F; Takaichi K
Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S133. PubMed ID: 21385558
[No Abstract] [Full Text] [Related]
2. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
Tanaka T; Kuwahara Y; Shima Y; Hirano T; Kawai M; Ogawa M; Arimitsu J; Hagihara K; Narazaki M; Ogata A; Kawase I; Kishimoto T
Arthritis Rheum; 2009 Dec; 61(12):1762-4. PubMed ID: 19950316
[No Abstract] [Full Text] [Related]
3. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of rheumatoid vasculitis-associated skin ulcer with a TNF-α antagonist.
Ashida A; Murata H; Mikoshiba Y; Ohashi A; Kobayashi A; Koga H; Uhara H; Okuyama R
Int J Dermatol; 2014 Feb; 53(2):e154-6. PubMed ID: 23557520
[No Abstract] [Full Text] [Related]
5. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
7. The rapid efficacy of abatacept in a patient with rheumatoid vasculitis.
Fujii W; Kohno M; Ishino H; Nakabayashi A; Fujioka K; Kida T; Nagahara H; Murakami K; Nakamura K; Seno T; Yamamoto A; Kawahito Y
Mod Rheumatol; 2012 Aug; 22(4):630-4. PubMed ID: 22124545
[TBL] [Abstract][Full Text] [Related]
8. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody.
Kubandova Z; Mathieu S; Pourtier C; Soubrier M
Joint Bone Spine; 2010 Dec; 77(6):623-4. PubMed ID: 20851657
[No Abstract] [Full Text] [Related]
9. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
10. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of digital tip necrosis in rheumatoid vasculitis with anti-CD20 antibody rituximab.
Korkosz M; Królczyk J; Telesińska-Jasiówka D; Grodzicki T
J Clin Rheumatol; 2013 Jan; 19(1):43-5. PubMed ID: 23319024
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6: a new therapeutic target.
Smolen JS; Maini RN
Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S5. PubMed ID: 16899109
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis.
Iijima T; Suwabe T; Sumida K; Hayami N; Hiramatsu R; Hasegawa E; Yamanouchi M; Hoshino J; Sawa N; Takaichi K; Oohashi K; Fujii T; Ubara Y
Mod Rheumatol; 2015 Jan; 25(1):138-42. PubMed ID: 24533557
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
15. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
González-Gay MA; Agudo M
Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
[No Abstract] [Full Text] [Related]
16. TNF blocker drugs used to fight inflammation go head-to-head. Adalimumab had highest treatment response and remission rates, etanercept has longest drug survival rates; infliximab placed third.
Duke Med Health News; 2010 Mar; 16(3):3. PubMed ID: 20461880
[No Abstract] [Full Text] [Related]
17. Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade.
Rech J; Ronneberger M; Englbrecht M; Finzel S; Katzenbeisser J; Manger K; Manger B; Schett G
Ann Rheum Dis; 2011 Feb; 70(2):390-2. PubMed ID: 20650873
[No Abstract] [Full Text] [Related]
18. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
Asahina A; Ishii N; Tohma S
J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
[No Abstract] [Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
[TBL] [Abstract][Full Text] [Related]
20. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
